Share This Article:

The Clinical Pharmacology of Propofol:A Brief Review

Full-Text HTML Download Download as PDF (Size:30KB) PP. 367-373
DOI: 10.4236/ojanes.2013.38078    4,006 Downloads   7,266 Views   Citations

ABSTRACT

The following article has been retracted due to the investigation of complaints received against it. The Editorial Board found that substantial portions of the text came from other published papers. The scientific community takes a very strong view on this matter, and the OJAnes treats all unethical behavior such as plagiarism seriously. This paper published in Vol.3 No. 8, 367-373pages, 2013, has been removed from this site.

Cite this paper

M. Hamd, "The Clinical Pharmacology of Propofol:A Brief Review," Open Journal of Anesthesiology, Vol. 3 No. 8, 2013, pp. 367-373. doi: 10.4236/ojanes.2013.38078.

References

[1] R. J. Fragen, “Diprivan (Propofol): A Historical Perspective,” Seminars in Anesthesia, Vol. 7, 1988, pp. 1-5.
[2] B. Kay and G. Rolly, “ICI 35 868: A New Intravenous Induction Agent,” Acta Anaesthesiologica Belgica, Vol. 28, 1977, pp. 303-307.
[3] H. M. Soliman, C. Mélot and J. L. Vincent, “Sedative and analgesic Practice in the Intensive Care Unit: The Results of a European Survey,” British Journal of Anesthesia, Vol. 87, No. 2, 2001, pp. 186-192.
http://dx.doi.org/10.1093/bja/87.2.186
[4] P. F. White, “Intravenous (Non-Opioid) Anesthesia,” Seminars in Anesthesia,” Perioperative Medicine and Pain, Vol. 24, No. 2, 2005, pp. 101-107.
http://dx.doi.org/10.1053/j.sane.2005.04.002
[5] M. Hynynen, K. Korttila and T. Tammisto, “Pain on IV Injection of Propofol (ICI 35868) in Emulsion Formulation. Short Communication,” Acta Anaesthesiologica Scandinavica, Vol. 29, No. 6, 1985, pp. 651-652.
http://dx.doi.org/10.1111/j.1399-6576.1985.tb02274.x
[6] I. Smith, P. F. White, M. Nathanson and R. Gouldson, “Propofol. An Update on Its Clinical Use,” Anesthesiology, Vol. 81, 1994, pp. 1005-1043.
http://dx.doi.org/10.1097/00000542-199410000-00028
[7] Y. Kotani, M. Shimazawa, Yoshimura, T. Iwama and H. Hara, “The Experimental and Clinical Pharmacology of Propofol, an Anesthetic Agent with Neuroprotective Properties,” CNS Neuroscience and Therapeutics, Vol. 14, No. 2, 2008, pp. 95-106.
http://dx.doi.org/10.1111/j.1527-3458.2008.00043.x
[8] L. Arts, R. Vanderhee and I. Dekker, “The Widely Used Anesthetic Agent Propofol Can Replace Alpha-Tocopherol as Antioxidant,” FEBS Letters, Vol. 357, No. 1, 1995, pp. 83-85.
http://dx.doi.org/10.1016/0014-5793(94)01337-Z
[9] O. Eriksson, P. Pollesello and E. N. Saris, “Inhibition of Lipid Peroxidation in Isolated Rat Liver Mitochondria by the General Anesthetic Propofol,” Biochemical Pharmacology, Vol. 44, No. 2, 1992, pp. 391-393.
http://dx.doi.org/10.1016/0006-2952(92)90026-F
[10] H. Chang, S. Y. Tsai and T. L. Chen, “Therapeutic Concentrations of Propofol Protects Mouse Macrophages from Nitric Oxide-Induced Cell Death and Apoptosis,” Canadian Journal of Anesthesia, Vol. 49, No. 5, 2002, pp. 477-480. http://dx.doi.org/10.1007/BF03017924
[11] M. H. Lebenbom-Mansour, S. K. Pandit and S. P. Kothary, “Desflurane versus Propofol Anesthesia: A Comparative Analysis in Outpatients,” Anesthesia and Analgesia, Vol. 76, 1993, pp. 936-94.
http://dx.doi.org/10.1213/00000539-199305000-00004
[12] M. S. Langley and R. C. Heel, “Propofol. A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Use as an Intravenous Anesthetic,” Drugs, Vol. 35, No. 4, 1988, pp. 334-372.
http://dx.doi.org/10.2165/00003495-198835040-00002
[13] P. S. Sebel and J. D. Lowdon, “Propofol: A New Intravenous Anesthetic,” Anesthesiology, Vol. 71, 1989, pp. 260-277.
http://dx.doi.org/10.1097/00000542-198908000-00015
[14] P. Ypsilantis, D. Mikroulis, M. Politou M, H. Tsoukali, M. Pitiakoudis, V. Didilis, G. Theodoridis, G. Bougioukas and C. Simopoulos, “Tolerance to Propofol’s Sedative Effect in Mechanically Ventilated Rabbits,” Anesthesia and Analgesia, Vol. 103, 2006, pp. 359-365.
http://dx.doi.org/10.1213/01.ane.0000223684.76783.bf
[15] M. T. Baker and M. Naguib, “Propofol: The Challenges of Formulation,” Anesthesiology, Vol. 103, 2005, pp. 860-876. http://dx.doi.org/10.1097/00000542-200510000-00026
[16] L. P. Briggs, R. S. J. Clarke and J. Watkins, “An Adverse Reaction to the Administration of Disoprofol (Diprivan),” Anesthesia, Vol. 37, No. 11, 1982, pp. 1099-1101.
http://dx.doi.org/10.1111/j.1365-2044.1982.tb01753.x
[17] G. F. Plummer, “Improved Method for the Determination of Propofol in Blood by High-Performance Liquid Chromatography with Fluorescence Detection,” Journal of Chromatography, Vol. 421, 1987, pp. 171-176.
http://dx.doi.org/10.1016/0378-4347(87)80394-8
[18] J. Schumacher, “Reptiles and Amphibians,” In: W. V. Lumb and E. W. Jones, Eds., Veterinary Anesthesia, 2nd Edition, Philadelphia, Williams and Wilkins, 1996.
[19] C. E. Short and A. Bufalari, “Propofol Anesthesia. Veterinary Clinics of North America: Small Animal Practice,” Vol. 29, 1999, pp. 747-778.
[20] G. Trapani, C. Altomare, G. Liso, E. Sanna and G. Biggio, “Propofol in Anesthesia. Mechanism of Action, Structure-Activity Relationships, and Drug Delivery,” Current Medicinal Chemistry, Vol. 7, No. 2, 2000, pp. 249-271.
http://dx.doi.org/10.2174/0929867003375335
[21] D. O. Ferreira, “Anesthetic Evaluation of Remifentanil during Routine Neurosurgical Procedures: Hemodynamic Responses and the Bispectral Index of the Electroencephalogram,” Veterinary Sciences, 2007
[22] T. Yamakura, K. Sakimura and K. Shimoji, “Direct Inhibition of the N-Methyl-D-aspartate Receptor Channel by High Concentrations of Opioids,” Anesthesiology, Vol. 91, 1999, pp. 1053-1063.
http://dx.doi.org/10.1097/00000542-199910000-00026
[23] I. D. Cockshott, E. J. Douglas, G. F. Plummer and P. J. Simons, “The Pharmacokinetics of Propofol in Laboratory Animals,” Xenobiotica, Vol. 22, No. 3, 1992, pp. 369-375. http://dx.doi.org/10.3109/00498259209046648
[24] T. Kirkpatrick, I. D. Cockshott, E. J. Douglas and W. S. Nimmo, “Pharmacokinetics of Propofol (Diprivan) in Elderly Patients,” British Journal of Anesthesia, Vol. 60, 1988, pp. 146-150.
[25] L. Aguilera and M. K. Zamacona, “Severe Protein Binding of Propofol in Patients with Severe Hypoalbuminaemia,” British Journal of Anesthesia, Vol. 74, 1995, pp. 81-90.
[26] J. X. Mazoit and K. Samii, “Binding of Propofol to Blood Components: Implications for Pharmacokinetics and for Pharmacodynamics,” British Journal of Clinical Pharmacology, Vol. 47, No. 1, 1999, pp. 35-42.
http://dx.doi.org/10.1046/j.1365-2125.1999.00860.x
[27] R. N. Upton, G. L. Ludbrook, C. Grant and A. M. Martinez, “Cardiac Output Is a Determinant of the Initial Concentrations of Propofol after Short-Infusion Administration,” Anesthesia and Analgesia, Vol. 89, 1999, pp. 545-552.
[28] A. Bienert, Z. Zaba, E. Grzeskowiak, K. Kusza and T. Grabowski, “Pharmacokinetics and Pharmacodynamics of Propofol during Propofol-Alfentanil and Propofol-Remifentanil Total Intravenous Anesthesia Monitored by Spectral Frequency Index,” Medical Science Monitor, Vol. 15, 2009, pp. 147-153.
[29] J. Kanto and E. Gepts, “Pharmacokinetic Implications for the Clinical Use of Propofol,” Clinical Pharmacokinetics, Vol. 17, No. 5, 1989, pp. 308-326.
http://dx.doi.org/10.2165/00003088-198917050-00002
[30] D. L. Zoran, D. H. Riedesel and D. C. Dyer, “Pharmacokinetics of Propofol in Mixed-Breed Dogs and Greyhounds,” American Journal of Veterinary Research, Vol. 54, 1993, pp. 755-760.
[31] I. D. Cockshott, L. P. Briggs, E. J. Douglas and M. White, “Pharmacokinetics of Propofol in Female Patients. Studies Using Single Bolus Injections,” British Journal of Anesthesia, Vol. 59, No. 9, 1987, pp. 1103-1110.
http://dx.doi.org/10.1093/bja/59.9.1103
[32] E. Gepts, F. Camu, I. D. Cockshott and E. J. Douglas, “Deposition of Propofol Administrated as Constant Rate Intravenous Infusion in Humans,” Anesthesia and Analgesia, Vol. 66, 1987, pp. 1256-1263.
http://dx.doi.org/10.1213/00000539-198712000-00010
[33] A. Shafer, V. A. Doze, S. L. Shafer and P. F. White, “Pharmacokinetics and Pharmacodynamics of Propofol Infusion during General Anesthesia,” Anesthesiology, Vol. 69, 1988, pp. 348-356.
http://dx.doi.org/10.1097/00000542-198809000-00011
[34] S. L. Shafer and D. R. Stanski, “Improving the Clinical Utility of Anesthetic Drug Pharmacokinetics,” Anesthesiology, Vol. 76, 1992, pp. 327-330.
http://dx.doi.org/10.1097/00000542-199203000-00001
[35] K. McKeage and C. M. Perry, “Propofol: A Review of Its Use in Intensive Care Sedation of Adults,” CNS Drugs, Vol. 17, No. 4, 2003, pp. 235-272.
http://dx.doi.org/10.2165/00023210-200317040-00003
[36] S. N. Bennett, M. M. McNeil, L. A. Bland, M. J. Arduino, M. E. Villarino, D. M. Perrotta, D. R. Burwen, S. F. Welbel, D. A. Pegues, L. Stroud, P. S. Zeitz and W. R. Jarvis, “Postoperative Infections Traced to Contamination of an Intravenous Anesthetic, Propofol,” New England Journal of Medicine, Vol. 333, No. 3, 1995, pp. 147-154.
http://dx.doi.org/10.1056/NEJM199507203330303
[37] B. Vasile, F. Rasulo, A. Candiani and N. Latronico, “The Pathophysiology of Propofol Infusion Syndrome: A Simple Name for a Complex Syndrome,” Intensive Care Medicine, Vol. 29, No. 9, 2003, pp. 1417-1425.
http://dx.doi.org/10.1007/s00134-003-1905-x
[38] P. Ypsilantis, M. Politou, D. Mikroulis, M. Pitiakoudis, M. Lambropoulou, C. Tsigalou, V. Didilis, G. Bougioukas, N. Papadopoulos, C. Manolas and C. Simopoulos, “Organ Toxicity and Mortality in Propofol-Sedated Rabbits under Prolonged Mechanical Ventilation,” Anesthesia and Analgesia, Vol. 105, No. 1, 2007, pp. 155-166.
http://dx.doi.org/10.1213/01.ane.0000265544.44948.0b
[39] M. L. Price, B. Millar, M. Grounds and J. Cashman, “Changes in Cardiac Index and Estimated Systemic Vascular Resistance during Induction of Anesthesia, with Thiopentone, Methohexitone, Propofol and Etomidate,” British Journal of Anesthesia, Vol. 69, No. 2, 1992, pp. 172-176. http://dx.doi.org/10.1093/bja/69.2.172
[40] A. Coetzee, P. Fourie, J. Coetzee, E. Badenhorst, A. Rebel, C. Bolliger, R. Uebel, C. Wium and C. Lombard, “Effect of Various Propofol Plasma Concentrations on Regional Myocardiac Contractility and Left Ventricular Afterload,” Anesthesia and Analgesia, Vol. 69, No. 4, 1989, pp. 473-483.
[41] J. P. Mulier, P. F. Wouters, H. Van Aken, G. Vermaut and E. Vandermeersch, “Cardiodynamic Effects of Propofol in Comparison with Thiopental,” Anesthesia and Analgesia, Vol. 72, No. 1, 1991, pp. 28-35.
http://dx.doi.org/10.1213/00000539-199101000-00006
[42] M. M. Glowaski and L. A. Wetmore, “Propofol: Application in Veterinary Sedation and Anesthesia,” Clinical Techniques in Small Animal Practice, Vol. 14, No. 1, 1999, pp. 1-9. http://dx.doi.org/10.1016/S1096-2867(99)80021-8
[43] P. Lerche, A. M. Nolan and J. Reid, “Comparative Study of Propofol or Propofol and Ketamine for the Induction of Anesthesia in Dogs,” Veterinary Record, Vol. 146, No. 20, 2000, pp. 571-574.
http://dx.doi.org/10.1136/vr.146.20.571
[44] C. Baumgartner, M. Bollerhey, J. Henke, S. Wagner, M. Ungerer and W. Erhardt, “Effects of Propofol on Ultrasonic Indicators of Hemodynamic Function in Rabbits,” Veterinary Anesthesia and Analgesia, Vol. 35, No. 2, 2008, pp. 100-112.
http://dx.doi.org/10.1111/j.1467-2995.2007.00360.x
[45] T. Brussel, J. L. Theissen, G. Vigfusson, P. P. Lunkenheimer, H. Van Aken and P. Lawin, “Hemodynamic and Cardiodynamic Effects of Propofol and Etomidate: Negative Inotropic Properties of Propofol,” Anesthesia and Analgesia, Vol. 69, No. 1, 1989, pp. 35-40.
[46] C. S. Goodchild and J. M. Serrao, “Cardiovascular Effects of Propofol in the Anaesthetized Dog,” British Journal of Anesthesia, Vol. 63, No. 1, 1989, pp. 87-92.
http://dx.doi.org/10.1093/bja/63.1.87
[47] J. A. Smith, J. S. Gaynor, R. M. Bednarski and W. W. Muir, “Adverse Effects of Administration of Propofol with Various Preanesthetic Regimens in Dogs,” Journal of the American Veterinary Medical Association, Vol. 202, No. 7, 1993, pp. 1111-1115.
[48] J. S. C. McCollum, K. R. Milligan and J. W. Dundee, “The Antiemetic Action of Propofol,” Anesthesia, Vol. 43, No. 3, 1988, pp. 239-240.
http://dx.doi.org/10.1111/j.1365-2044.1988.tb05551.x
[49] S. A. Blakey and J. A. Hixson-Wallace, “Clinical Significance of Rare and Benign Side Effects: Propofol and Green Urine,” Pharmacotherapy, Vol. 20, No. 9, 2000, pp. 1120-1122.
http://dx.doi.org/10.1592/phco.20.13.1120.35041
[50] P. Barker, J. A. Langton, I. G. Wilson and G. Smith, “Movements of the Vocal Cords on Induction of Anesthesia with Thiopentone or Propofol,” British Journal of Anesthesia, Vol. 69, No. 1, 1992, pp. 23-25.
http://dx.doi.org/10.1093/bja/69.1.23
[51] A. Adetunji, R. and A. Ajadi, “Total Intravenous Anesthesia with Propofol: Repeat Bolus versus Continuous Propofol Infusion Technique in Xylazine Premedicated Dogs,” Israel Journal of Veterinary Medicine, Vol. 52, 2002, pp. 139-145.
[52] E. Oklu, F. S. Bulutcu, Y. Yalcin, U. Ozbek, E. Cakali and O. Bayindir, “Which Anesthetic Agent Alters the Hemodynamic Status during Pediatric Catheterization? Comparison of Propofol versus Ketamine,” Journal of Cardiothoracic and Vascular Anesthesia, Vol. 17, No. 6, 2003, pp. 686-890. http://dx.doi.org/10.1053/j.jvca.2003.09.009
[53] V. A. Peduto, A. Concas, G. Santoro, G. Biggio, G. L. Gessa, “Biochemical and Biophysiological Evidence That Propofol Enhances GABA-Ergic Transmission in the Rat Brain,” Anesthesiology, Vol. 75, 1991, pp. 1000-1009.
[54] A. Silva, “Recent Advances in Veterinary Anesthesiology: Towards Closed-Loop Systems,” Veterinary Sciences, 2007.
[55] D. L. Weir, C. S. Goodchild and D. I. Graham, “Propofol: Effects on Indices of Cerebral Ischemia,” Journal of Neurosurgical Anesthesiology, Vol. 1, No. 3, 1989, pp. 284-829. http://dx.doi.org/10.1097/00008506-198909000-00014
[56] M. A. Mirski, B. Muffelman, J. A. Ulatowski and D. F. Hanley, “Sedation for the Critically Ill Neurologic Patient,” Critical Care Medicine, Vol. 23, No. 12, 1995, pp. 2038- 2053.
http://dx.doi.org/10.1097/00003246-199512000-00013
[57] P. E. Marik, “Propofol: Therapeutic Indications and SideEffects,” Current Pharmaceutical Design, Vol. 10, No. 29, 2004, pp. 3639-3649.
http://dx.doi.org/10.2174/1381612043382846
[58] G. W. Chang and P. C. Kam, “The Physiological and Pharmacological Roles of Cytochrome P450 Isoenzymes,” Anesthesia, Vol. 54, No. 1, 1999, pp. 42-50.
http://dx.doi.org/10.1046/j.1365-2044.1999.00602.x
[59] W. C. Bowman, “Pharmacology of Intravenous Anesthetics and Hypnotics in General Anesthesia,” 5th Edition, Butterworths, London, 1989.
[60] T. Murayama, Y. Sato, T. Wainai, A. Enomoto, N. Seo, H. Yoshino and E. Kobayashi, “Effect of Continuous Infusion of Propofol on Its Concentration in Blood with and without the Liver in Pigs,” Transplantation Proceedings, Vol. 37, No. 10, 2005, pp. 4567-4570.
http://dx.doi.org/10.1016/j.transproceed.2005.11.011
[61] P. Favetta, C. S. Degoute, Perdrix, C. Dufresne, R. Boulieu and J. Guitton, “Propofol Metabolites in man Following Propofol Induction and Maintenance,” British Journal of Anesthesia, Vol. 88, No. 5, 2002, pp. 653-658.
http://dx.doi.org/10.1093/bja/88.5.653
[62] L. Z. Benet and D. L. Kroetz, “Pharmacokinetics. Goodman and Gilman’s: The Pharmacological Basis of Therapeutics,” The McGraw-Hill Company, New York, 1996.
[63] A. L. Dawidowicz, E. Fornal, M. Mardarowicz and A. Fijalkowska, “The Role of Human Lungs in the Biotransformation of Propofol,” Anesthesiology, Vol. 93, No. 4, 2000, pp. 992-997.
http://dx.doi.org/10.1097/00000542-200010000-00020
[64] M. H. Court, S. X. Duan, L. M. Hesse, K. Venkatakrishnan and D. J. Greenblatt, “Cytochrome P-450 2B6 is Responsible for Interindividual Variability of Propofol Hydroxylation by Human Liver Microsomes,” Anesthesiology, Vol. 94, No. 1, 2001, pp. 110-119.
http://dx.doi.org/10.1097/00000542-200101000-00021
[65] C. Le Guellec, B. Lacarelle, P. H. Villard, H. Point, J. Catalin and J. Durand, “Glucuronidation of Propofol in Microsomal Fractions from Various Tissues and Species Including Humans: Effect of Different Drugs,” Anesthesia and Analgesia, Vol. 81, No. 4, 1995, pp. 855-861.
[66] S. L. Shafer, “Advances in Propofol Pharmacokinetics and Pharmacodynamics,” Journal of Clinical Anesthesia, Vol. 11, 1993, pp. 12-13.
[67] P. A. Gray, G. R. Park, I. D. Cockshott, E. J. Douglas, B. Shuker and P. J. Simons, “Propofol Metabolism in Man during the Anhepatic and Reperfusion Phases of Liver Transplantation,” Xenobiotica, Vol. 22, No. 1, 1992, pp. 105-114. http://dx.doi.org/10.3109/00498259209053107
[68] P. Veroli, B. O’Kelly, F. Bertrand, J. H. Trouvin, R. Farinotti and C. Ecoffey, “Extrahepatic Metabolism of Propofol in Man during the Anhepatic Phase of Orthotopic Liver Transplantation,” British Journal of Anesthesia, Vol. 68, No. 2, 1992, pp. 183-186.
http://dx.doi.org/10.1093/bja/68.2.183
[69] S. H. Zhang, Q. Li, S. L. Yao and B. X. Zeng, “Subcellular Expression of UGT1A6 and CYP1A1 Responsible for Propofol Metabolism in Human Brain,” Acta Pharmacological Sinica, Vol. 22, No. 11, 2001, pp. 1013-1017.

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.